Zenapax Related Published Studies
Well-designed clinical trials related to Zenapax (Daclizumab)
A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. [2007.05]
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. [2007.03]
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. [2007.03]
Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. [2006.07.15]
Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. [2006.05]
A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. [2006.04]
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. [2005.09]
Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. [2005.08.27]
Daclizumab to prevent rejection after cardiac transplantation. [2005.06.30]
Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. [2005.06]
Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial. [2005.05]
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. [2005.04.15]
Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. [2005.03]
Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. [2005.01]
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. [2004.09.01]
One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. [2004.05]
Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. [2004]
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. [2003.12]
Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab. [2003.08]
Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. [2003.04.27]
Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. [2003.01]
A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. [2002.02]
Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. [2002]
Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. [2001.12]
Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. [2001.11.27]
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. [2001.09.15]
Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. [2000]
Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. [1999.07.27]
Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. [1999.01.15]
Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. [1998.01.15]
Well-designed clinical trials possibly related to Zenapax (Daclizumab)
Reduced exposure to calcineurin inhibitors in renal transplantation. [2007.12.20]
Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. [2007.10.15]
Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients. [2007.04]
High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. [2006.11.15]
WOFIE stimulates regulatory T cells: a 2-year follow-up of renal transplant recipients. [2006.06.15]
Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. [2006.04]
Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. [2006]
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. [2005.08.27]
Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. [2005.08]
A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation. [2005.03]
Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. [2005.03]
Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients. [2005.03]
The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation. [2005.03]
No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. [2004.07.15]
Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. [2004.05]
Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. [2004.05]
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. [2004.01.27]
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. [2003.11]
[Cytokines and growth factors serum level and renal allograft function (preliminary report)] [2003.10]
The role of the protocol biopsies in renal allograft recipients. [2003.09]
Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. [2003.09]
Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. [2003.05.27]
WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. [2003.04.27]
Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. [2002.07]
Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. [2000.03.02]
The use of antibodies against the IL-2 receptor in transplantation. [1998.10]
Other research related to Zenapax (Daclizumab)
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. [2008.10.23]
Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma. [2008.09.11]
Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. [2008.09]
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. [2008.09]
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. [2008.07.15]
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. [2008.06.19]
Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients? [2008.06]
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.06]
Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. [2008.06]
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. [2008.03]
Sinus bradycardia associated with daclizumab in liver transplant recipients: report of 3 cases. [2008.03]
Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. [2008.03]
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.02.05]
Daclizumab for treatment of birdshot chorioretinopathy. [2008.02]
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] [2008.01]
Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. [2008]
[Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant] [2008]
Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. [2007.12]
Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. [2007.11]
Daclizumab. [2007.10]
Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience. [2007.09]
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. [2007.09]
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. [2007.08.21]
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. [2007.08]
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. [2007.08]
A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience. [2007.06]
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. [2007.05.28]
Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. [2007.04.15]
Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation. [2007.03.07]
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. [2007.03]
Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. [2007.01]
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. [2007.01]
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. [2006.11]
Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. [2006.11]
Induction therapy with daclizumab in heart transplantation--how many doses? [2006.10]
Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. [2006.09]
Novel treatment of Sezary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody). [2006.09]
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. [2006.08.01]
Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. [2006.08]
The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. [2006.06]
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. [2006.04.11]
Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). [2006.02.07]
Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. [2006.02]
Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study. [2006.01.04]
Daclizumab for children with corticosteroid refractory graft-versus-host disease. [2006.01]
|
